- Home
- ARGX vs TCOM Comparison
ARGX vs TCOM Comparison
Compare ARGX & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- TCOM
- Stock Information
- Founded
- ARGX 2008
- TCOM 1999
- Country
- ARGX Netherlands
- TCOM Singapore
- Employees
- ARGX N/A
- TCOM N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- TCOM Hotels/Resorts
- Sector
- ARGX Health Care
- TCOM Consumer Discretionary
- Exchange
- ARGX Nasdaq
- TCOM Nasdaq
- Market Cap
- ARGX 37.3B
- TCOM 42.1B
- IPO Year
- ARGX 2017
- TCOM 2003
- Fundamental
- Price
- ARGX $623.82
- TCOM $72.44
- Analyst Decision
- ARGX Strong Buy
- TCOM Strong Buy
- Analyst Count
- ARGX 20
- TCOM 10
- Target Price
- ARGX $634.50
- TCOM $74.18
- AVG Volume (30 Days)
- ARGX 290.3K
- TCOM 3.6M
- Earning Date
- ARGX 10-31-2024
- TCOM 11-18-2024
- Dividend Yield
- ARGX N/A
- TCOM N/A
- EPS Growth
- ARGX N/A
- TCOM 50.61
- EPS
- ARGX N/A
- TCOM 3.40
- Revenue
- ARGX $1,908,659,000.00
- TCOM $7,252,833,407.00
- Revenue This Year
- ARGX $61.99
- TCOM $19.96
- Revenue Next Year
- ARGX $42.48
- TCOM $15.03
- P/E Ratio
- ARGX N/A
- TCOM $21.28
- Revenue Growth
- ARGX 85.56
- TCOM 29.74
- 52 Week Low
- ARGX $349.86
- TCOM $33.67
- 52 Week High
- ARGX $644.97
- TCOM $77.18
- Technical
- Relative Strength Index (RSI)
- ARGX 58.04
- TCOM 58.70
- Support Level
- ARGX $613.95
- TCOM $71.32
- Resistance Level
- ARGX $644.97
- TCOM $74.70
- Average True Range (ATR)
- ARGX 14.33
- TCOM 1.85
- MACD
- ARGX -0.42
- TCOM 0.07
- Stochastic Oscillator
- ARGX 50.28
- TCOM 58.57
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About TCOM Trip.com Group Limited
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from its online platform, but the company also maintains offline call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.